VBS VetVerlag, Buchhandel und Seminar GmbH
World's Elite Specialists in Veterinary Rehabilitation- and Sports Medicine Meet in Ghent - Eagerly Awaited Standard Work is Going to be Presented by the Main Authors
mehr
Storys zum Thema Gesundheit / Medizin
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Sysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...
mehrLiquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)
Hamburg, Germany (ots) - Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM(TM) ...
mehrWord Weer Mens - Cookbook, Specialist Book, Health Book ... and Much More
mehrSysmex Inostics OncoBEAM(TM)-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study
Hamburg/Baltimore (ots) - Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR ...
mehrSysmex Inostics' SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM(TM) enhanced digital PCR technology for detection of mutations in circulating tumor DNA
Hamburg/Baltimore (ots) - Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics' novel ...
mehrEuropean Association of E-Pharmacies (EAEP)
EAMSP kicks off information campaign about digitization in German healthcare sector / Fighting the allergic reaction to anything new with #neuschnupfen
mehrWorldwide first and only shotgun lipidomics service provider with official GMP certificate
Dresden / Germany (ots) - Good Manufacturing Practices (GMP) ensure safety and quality of pharmaceutical products. Lipotype is the worldwide first and only officially GMP certified shotgun lipidomics service provider for pharmaceutical applications. Quality variations can pose direct threats to patient health - especially in the pharma industry. This is why quality ...
mehrLEUKOCARE Announces Appointment of Dr Andreas Seidl as new Chief Operating Officer and member of the Executive Board
Munich, Germany (ots) - Dr Andreas Seidl, hired as new Chief Operating Officer and member of the Executive Board, will be responsible for managing R&D operations as well as quality and regulatory, logistics and intellectual property of LEUKOCARE AG. He will assume his new role on April 1, 2019. Munich-based ...
mehrA new force in the European chemical and pharmaceutical engineering sector: TTP AG is now also acquiring the French subsidiary of NNE A/S
Frankfurt am Main/Copenhagen (ots) - TTP AG, Frankfurt/Main and its subsidiary TTP France S.A.S. are now also acquiring NNE S.A.S., the French engineering arm of the Danish company NNE A/S with 87 employees at the pharmaceutical industry sites in Paris, Lyon and Chartres. Three weeks ago, TTP AG and NNE A/S ...
mehrSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
mehrLipotype announces "Lipidomics Excellence Award" for Breakthrough Lipidomics Projects / Call for Applications open till 30 March, 2019
Dresden/Germany (ots) - The international scientific community is called to submit applications for the premiere of the world's first award for cutting edge contributions to the progress of life sciences through lipidomics, the 2019 "Lipidomics Excellence Award" (LEA) until 30 March, 2019. Prof. Dr. Kai Simons, ...
mehrCardiovascular diseases and nutrition in Europe: every second to third premature death preventable
mehrDr. Klemens Schulz appointed CPO of the L&R Corporate Group
mehrInvisible self-disinfection: "wipe-on glass" enables permanent hygiene and protection from infection through creation of antimicrobial surfaces
mehrSysmex Inostics OncoBEAM(TM) circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
mehrSysmex Inostics' OncoBEAM(TM) platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
mehrSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
mehrEuropean Society for Medical Oncology (ESMO)
Breast cancer patients use Twitter as a non-medical forum to share their experiences
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
mehrBritta Fuenfstueck appointed as new CEO of the HARTMANN GROUP
mehrIndia hosts the Mahatma Gandhi International Sanitation Convention / 29th September to 2nd October 2018, New Delhi
New Delhi (ots) - Ministers and sanitation sector leaders from around the world will convene this month at the Mahatma Gandhi International Sanitation Convention (MGISC) in New Delhi. Hosted by the Government of India, this event will be an opportunity for delegates to exchange sanitation successes and best ...
mehrEuropean Society for Medical Oncology (ESMO)
ESMO emphasises importance of cancer on global health agenda at WHA
Lugano (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100006433?langid=2 - At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. ESMO advocated the strengthening of health systems to achieve Universal Health Coverage and to provide ...
mehrHitachi Medical Systems Europe Holding AG
Hitachi Medical Systems Europe announces "ScanSync" - a new function for diagnostic ultrasound that reduces the burden on operators - which is to be supported by the "ARIETTA Prologue"
Vienna (ots) - - Indication: Picture can be downloaded free of charge under: http://www.presseportal.ch/de/nr/100012989?langid=2 - This function enables the operation of the diagnostic ultrasound system via auto detection of transducer movement. Hitachi Medical Systems Europe, a wholly owned subsidiary of Hitachi, ...
mehrPersonnel Change in Executive Board of L&R
Vienna/Rengsdorf (ots) - In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned. The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new ...
mehrUMIT - The Health & Life Sciences University
2UMIT Professor Uwe Siebert receives SMDM Award and becomes SMDM President
mehrBoehringer Ingelheim's afatinib Achieves Primary Endpoint in Global Phase III Study in Recurrent/Metastatic Head and Neck Squamous Cell Cancer
Ingelheim, Germany (ots/PRNewswire) - - Results from the LUX-Head & Neck 1 study show afatinib* significantly delayed tumour growth versus chemotherapy in patients following failure of their previous treatment, reducing the risk for disease progression by 20% - Head and neck cancer has a very poor prognosis with no ...
mehrBoehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany (ots/PRNewswire) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], ...
mehrFlibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Ingelheim, Germany, November 16 (ots/PRNewswire) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at ...
mehrBoehringer Ingelheim Receives Approval From the European Commission for Mirapexin(R)/Sifrol(R) Prolonged-Release, Once Daily Tablet for the Treatment of Parkinson's Disease
Ingelheim, Germany (ots/PRNewswire) - - New Formulation Brings the Established Efficacy of Mirapexin(R)/Sifrol(R) to Patients With Parkinson's Disease in the Convenience of a Once Daily Dose Boehringer Ingelheim today announced that the Mirapexin(R)/Sifrol(R) (pramipexole) new prolonged-release , once daily tablet ...
mehrBoehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical ...
mehr
Vorherige234567891011Nächste